Scarica l'app Stockscreener
5.14
7.53%
0.36
Trisalus Life Sciences Inc Borsa (TLSI) Ultime notizie
TriSalus Life Sciences announces publication of pre-clinical data - Yahoo Finance
TriSalus's TriNav System Shows Breakthrough 227% Increase in Liver Cancer Drug Delivery Efficacy - StockTitan
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
TLSITriSalus Life Sciences, Inc. Latest Stock News & Market Updates - StockTitan
TriSalus Announces Leadership Changes and New Incentive Program - TipRanks
TriSalus Life Sciences names new finance chief - MSN
TriSalus Has Several Leadership Changes - MPO-mag
TriSalus Life Sciences reshuffles executive team - Investing.com
TriSalus Life Sciences Taps James Young as CFO - MarketWatch
TriSalus Life Sciences Strengthens Executive Team with Strategic Leadership Appointments for 2025 - StockTitan
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 22.8% in December - MarketBeat
TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut - Seeking Alpha
Cantor Fitzgerald Initiates Coverage of TriSalus Life Sciences (TLSI) with Overweight Recommendation - MSN
Intrahepatic Cholangiocarcinoma Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics - The Globe and Mail
Trisalus life sciences officer sells $1,394 in stock By Investing.com - Investing.com Canada
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Acquires $249,998.84 in Stock - MarketBeat
Frankenius equity AB acquires shares in Trisalus Life Sciences for $249,998 - Investing.com
Trisalus life sciences officer sells $1,394 in stock - Investing.com
TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Cantor Fitzgerald - Defense World
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $12.08 Consensus Price Target from Analysts - Defense World
Great-West Lifeco Inc. (TSE:GWO) Receives C$47.63 Consensus Price Target from Analysts - Defense World
Analysts Set Forward Air Co. (NASDAQ:FWRD) PT at $39.25 - Defense World
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33 - Defense World
Safe Bulkers (NYSE:SB) versus Euronav (NYSE:CMBT) Financial Survey - Defense World
Stock Traders Buy High Volume of Call Options on Teva Pharmaceutical Industries (NYSE:TEVA) - Defense World
TriSalus Life Sciences Forms Strategic Partnership With Geo-Med - MPO-mag
TriSalus Expands PEDD Portfolio - MPO-mag
Cantor Fitzgerald Initiates Coverage on TriSalus Life Sciences (NASDAQ:TLSI) - MarketBeat
Brokerages Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Target Price at $12.08 - MarketBeat
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Significant Increase in Short Interest - MarketBeat
TriSalus Life Sciences director sells $110,700 in stock By Investing.com - Investing.com Canada
TriSalus Life Sciences director sells $110,700 in stock - Investing.com India
Director Arjun Desai Sells 30,000 Shares of TriSalus Life Sciences Inc (TLSI) - GuruFocus.com
Liver Cancer Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight - EIN News
Northland Capmk Brokers Increase Earnings Estimates for TLSI - MarketBeat
Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock - Investing.com
Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock By Investing.com - Investing.com UK
Friday's Insider Moves: Top Executives Make Notable Stock Transactions - Investing.com India
TriSalus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock By Investing.com - Investing.com Australia
Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock - Investing.com India
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Canaccord Genuity Group Lowers TriSalus Life Sciences (NASDAQ:TLSI) Price Target to $11.00 - Defense World
Canaccord cuts TriSalus shares target, keeps buy rating on Q3 report - Investing.com Canada
TriSalus Life Sciences (NASDAQ:TLSI) Given New $11.00 Price Target at Canaccord Genuity Group - MarketBeat
TriSalus Life Sciences Inc (TLSI) Quarterly 10-Q Report - Quartzy
MedTech Acquisition (OTCMKTS:MTACU) Files 8-K Report with SEC Announcement - Defense World
TriSalus Life Sciences Reports Strong Q3 Growth - TipRanks
TriSalus Reports Q3 2024 Financial Results and Provides Business Update - BioSpace
TriSalus Life Sciences Revenue Soars 42% in Q3, Expands into $375M Market | TLSI Stock News - StockTitan
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Previe - GuruFocus.com
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Q3 Earnings Estimate for TLSI Issued By Roth Capital - MarketBeat
1.91%
2.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):